Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
Titel:
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
Auteur:
Eghtedar, Alireza Verstovsek, Srdan Estrov, Zeev Burger, Jan Cortes, Jorge Bivins, Carol Faderl, Stefan Ferrajoli, Alessandra Borthakur, Gautam George, Solly Scherle, Peggy A. Newton, Robert C. Kantarjian, Hagop M. Ravandi, Farhad